Home /
health Podcasts /
Medical Digest & Congress Report /
Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

EPISODE · Jan 21, 2026 · 9 MIN

Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

from Medical Digest & Congress Report · host Medical Congress News

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the HER2CLIMB-05 trail that were presented at the San Antonio Breast Cancer Symposium 2025.Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-3-adding-tucatinib-first-line-maintenance-therapy-delayed-disease-progression-her2-positive-metastatic-breast-cancer-her2climb-05-trial

Episode metadata supplied by the publisher feed · Published Jan 21, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

0:00 9:07

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 9 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 21, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!